I have been afforded the great privilege of a perch at Forbes Online from which to communicate my perspective on events where health policy and healthcare finance intersect. Avik Roy, an equity research analyst at Monness, Crespi, Hardt & Co. in New York City, has invited me to collaborate with him on his blog, The Apothecary, which has been hosted by Forbes for a few months.
What I intend to contribute at The Apothecary is somewhat different than what you'll read in my other media, because I'll be bringing financial analysis to bear on the healthcare space (although not ignoring what the politicians and bureaucrats are doing, of course. Any healthcare enterprise's success will depend largely on government action.)
Many Wall Street analysts have been after Pfizer, Inc., to restructure and refocus for years. Under new CEO, Ian Reid, they think they've finally got someone whom they believe can get the job done. But others think that Big Pharma should grow by acquisitions, instead of shrinking by spinning off divisions. How credible is it that Mr. Reid will take the latter course? Read my entire blog entry here.
What I intend to contribute at The Apothecary is somewhat different than what you'll read in my other media, because I'll be bringing financial analysis to bear on the healthcare space (although not ignoring what the politicians and bureaucrats are doing, of course. Any healthcare enterprise's success will depend largely on government action.)
Many Wall Street analysts have been after Pfizer, Inc., to restructure and refocus for years. Under new CEO, Ian Reid, they think they've finally got someone whom they believe can get the job done. But others think that Big Pharma should grow by acquisitions, instead of shrinking by spinning off divisions. How credible is it that Mr. Reid will take the latter course? Read my entire blog entry here.
Comments
Post a Comment